Tarrytown, NY (PRWEB) May 20, 2010
The Walden Group, Inc., a specialized investment banking firm focused on merger and acquisition (M&A) and strategic growth services for companies in the healthcare industry, is pleased to announce that Daniel J. Doyle and Diane Thome are now associated with the firm.
Mr. Doyle is the former President of C.R. Bard's Patient Care Division where he grew sales several-fold, substantially raised profit margins and completed several corporate acquisitions and licensing transactions. He was also Director of Business Development for C.R. Bard Corporate, where he was responsible for growth strategies for Bard Access, Davol, Bard Urology, Bard Medical, and Bard Endoscopic Technologies. At Bard's Patient Care Division, Mr. Doyle headed up a 225-person organization that manufactures and markets disposable devices and equipment sold to hospitals, physician’s offices, and home/long-term care markets.
Mr. Doyle is an expert in strategic planning, market assessments and introductions, and market share expansion. He brings to the table not only professional functionality of the highest order, but also the perspective and wisdom of a successful chief executive of a major healthcare firm. Since he left Bard, he has been called upon to provide these and other services for more than 65 companies, including Johnson & Johnson, GlaxoSmithKline, ConvaTec and many early smaller domestic and foreign companies.
Ms. Thome was an executive in charge of the Healthcare Practice for Opinion Research Corporation, a Director of Strategic Planning at Little Company of Mary Hospital, and Senior Director of Provider Development at MedCare HMO.
Under her own company, DT Research, Ms. Thome has provided cost-effective direct market research services by organizing incisive focus groups, physician feedback programs and expert market and product analysis. Ms. Thome's clients have included Behavioral Research, Inc, The American Academy of Orthopaedic Surgeons, and Axxiom Healthcare Alliance.
The Walden Group already employs a close-to-operations and strategic perspective to its M&A and consulting work, with a particular emphasis on helping clients build fundamental value and grow organically or by fitted acquisition.
With the addition of Dan Doyle and Diane Thome, the firm fortifies its strategic and M&A services and will provide the following additional offerings on a cost-effective, streamlined and high ROI basis:
- Evidence-based Strategic Planning with an informed, direct market-based seasoned approach
- Market assessments for new product introductions and repositions
- Competitive Analysis
- Sales and marketing advisory services with emphasis on improving sales force performance
- Physician and healthcare practitioner feedback, including in-depth interviews and targeted focus groups
- New Product Development
- Feasibility Studies and Needs Assessments
- U.S. Market Penetration Advice
A more description of these services is available at http://www.waldenmed.com/strategic.asp.
The Walden Group is a strategic healthcare investment banking firm specializing in merger and acquisition transactions and business development for healthcare companies. It assists public and private companies divest subsidiaries, divisions and product lines that no longer fit core strategic plans. It also conducts cost-effective strategic planning services, including focused acquisition searches and highly sophisticated, results-oriented business development and corporate growth functions. It also invests its own funds to advance the cause of promising opportunities. On a quarterly basis The Walden Group publishes The Strategic Healthcare M&A Report, which analyzes virtually all notable merger and acquisition transactions in the healthcare sector. It is available for free by contacting the firm at publications(at)waldenmed(dot)com.